2026年2月,加拿大的一项调查发现,有~3M成年人使用GLP-1药物进行体重、糖尿病或心脏健康,报告食欲减少和生活方式改变,尽管存在成本和覆盖面障碍。 In Feb 2026, a Canadian survey found ~3M adults used GLP-1 drugs for weight, diabetes, or heart health, reporting appetite reduction and lifestyle changes, despite cost and coverage barriers.

2026年2月对加拿大成人进行的调查发现,约有300万人使用GLP-1类药物,如Ozempic或Mounjaro,主要用于减肥、糖尿病或心脏健康。 A survey of Canadian adults conducted in February 2026 finds that about three million people are using GLP-1 drugs like Ozempic or Mounjaro, primarily for weight loss, diabetes, or heart health. 用户报告说食欲下降、渴望减少、比例较小、外出吃饭或饮酒频率降低。 Users report reduced appetite, fewer cravings, smaller portion sizes, and less frequent dining out or alcohol consumption. 许多人正在购买更多新鲜食品,并花在衣着、健身和个人护理上的钱更多。 Many are buying more fresh foods and spending more on clothing, fitness, and personal care. 尽管兴趣很大,但仍有超过200万的其他人因成本和保险范围有限而望而却步,只有28%的人得到全部保险。 Despite high interest, over two million others are deterred by cost and limited insurance coverage, with only 28% fully covered. 常见副作用包括恶心和消化问题,但严重的并发症很少见。 Common side effects include nausea and digestive issues, though serious complications are rare. 研究结果表明,由这些药物驱动的饮食和消费习惯发生了重大变化。 The findings suggest a significant shift in eating and spending habits driven by these medications.